Public Health Update: CDC Reminder of Recommendations for Seasonal Administration of Maternal RSV Vaccine

Updated:
January 21, 2026
Published:
February 2, 2024

What You Need To Know

On January 26, the CDC issued a Clinician Outreach and Communication Activity (COCA) message titled, Reminder of Recommendations for Seasonal Administration of Maternal RSV Vaccine. It reminds vaccine providers that the CDC recommends RSV vaccination (Abrysvo, Pfizer) for pregnant people 32 through 36 weeks and 6 days gestation to protect infants against RSV-associated lower respiratory tract disease (LRTD) after birth. The recommended season for vaccination during pregnancy ends on January 31 in most of the continental United States.

RECOMMENDATIONS FOR HEALTHCARE PROVIDERS

  •  In most of the continental United States, administer the maternal RSV vaccine (Pfizer Abrysvo) from September 1 through January 31.
  • Healthcare providers who administer the RSV vaccine to pregnant people after January 31 should encourage patients to check with their insurance plans on coverage details, as coverage and cost-sharing by private insurance plans may vary after January 31. Providers should consider submitting an insurance test claim to estimate out-of-pocket costs.
  • In jurisdictions where seasonality differs from most of the continental United States, such as Alaska, southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands, and the U.S. Virgin Islands, healthcare providers should follow state, local, or territorial guidance on timing of administering the RSV vaccine (Pfizer Abrysvo) for pregnant people.
  • CDC recommends protecting all infants against RSV-associated LRTD through either the RSV vaccine for pregnant people (Pfizer Abrysvo) or infant receipt of nirsevimab. Administration of both products is not needed for most infants.
  • For infants age less than 8 months born to unvaccinated mothers, healthcare providers should administer nirsevimab from October 1 through March 31; however, healthcare providers can administer nirsevimab outside of this timeframe based on local epidemiology.

RESOURCES AND REFERENCES